Abstract
Background Clinical trial guidelines for assessing the safety of vaccines, including the FDA criteria, are primarily based on subjective, self-reported questionnaires. Despite the tremendous technological advances in recent years, objective, continuous assessment of physiological measures post-vaccination is rarely performed.
Methods To evaluate the short-term effects of the BNT162b2 COVID-19 vaccine on physiological measures, we conducted a prospective observational study during the mass vaccination campaign in Israel. 160 individuals >18 years who were not previously found to be COVID-19 positive and who received the second dose of the COVID-19 vaccine between 1 January, 2021, and 13 March, 2021 were equipped with a chest-patch sensor and a dedicated mobile application. The chest-patch sensor continuously measured 13 physiological vitals one day before the inoculation (baseline), for four days: heart rate, blood oxygen saturation, respiratory rate, systolic and diastolic blood pressure, pulse pressure, mean arterial pressure, heart rate variability, stroke volume, cardiac output, cardiac index, systemic vascular resistance, and body temperature. The mobile application collected daily self-reported questionnaires starting one day before the inoculation, for 15 days on local and systemic reactions, sleep quality, stress levels, physical activity, and mood levels.
Findings Within the first 48 hours post-vaccination, we identified significant changes (p-value <0.05) in nearly all 13 chest-patch indicators compared to their baseline levels. 48.5% (n=78) reported no local or systemic reaction. Nevertheless, we identified considerable changes in chest-patch indicators during the first 48 hours post-vaccination also in this group of presumably asymptomatic participants. Within three days from vaccination, these measures returned to baseline levels in both groups, further supporting the safety of the vaccine.
Interpretation Our work underscores the importance of obtaining objective physiological data in addition to self-reported questionnaires when performing clinical trials, particularly in ones conducted in very short time frames.
Funding The European Research Council (ERC) project #949850.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Participants were scheduled for their vaccinations before study enrollment.
Funding Statement
This research was supported by the European Research Council (ERC) project #949850 and the Israel Science Foundation (ISF), grant No. 3409/19, within the Israel Precision Medicine Partnership program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Before participating in the study, all subjects were advised, both orally and in writing, as to the nature of the study and gave written informed consent to the study protocol (appendix pp 25-35), which was approved by the Tel-Aviv University Institutional Review Board (0002522-1). All data were de-identified, and no personal identifiable information was gathered.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Researchers interested in obtaining an aggregated version of the data sufficient to reproduce the results reported in this paper should contact the corresponding author. The study protocol is available at the appendix (pp 25-35). Statistical code will be available with publication.
